Comparison of COX-2 Drugs
The table below shows the various COX-2 inhibiting drugs, companies marketing the drugs, their COX-1/COX-2 selectivity ratios and sales volume.
| Drug Name | Drug Trade Name in the U.S. | Approved by FDA | Maker | Cox-1/ Cox-2 Ratio | Sales Volume in Billions |
|---|---|---|---|---|---|
| Rofecoxib | Vioxx | 05/1999 | Merck | 272 | $2.5 (1) |
| Celecoxib | Celebrex | 12/1998 | Pfizer | 30 | $3.2 (1) |
| Valdecoxib | Bextra | 11/2001 | Pfizer | 60 | $1.3 (2) |
| Lumiracoxib | Prexige | N/A | Novartis | 400 | $.5 (3) |
| Eterocoxib | Arcoxia | N/A | Merck | 344 | $.12 (4) |
1 Worldwide Sales 2003
2 Projected for 2004
3 Projected for 2007
COX-2 Inhibitors: Personal Injury Lawsuits
Manufacturers of COX-2 inhibitor drugs have a responsibility to provide consumers with pharmaceuticals that are reasonably safe. In addition, they have to inform physicians and patients about any known side effects associated with their products. Failure to comply with these requirements might render pharmaceutical companies financially liable for any harm suffered by patients who have taken their drugs. If you suspect that your cardiovascular symptoms were caused by COX-2 inhibitor, such as Vioxx, contact a knowledgeable personal injury lawyer to discuss your case and initiate prompt legal action. To provide their clients with comprehensive legal help in a variety of situations, many of the larger personal injury law firms employ attorneys specializing in other areas of law. For example, established injury practices often also offer the services of a skilled birth injury attorney, auto accident lawyer and DWI attorney.